Xarelto demonstrates reduced risk of heart failure in patients with atrial fibrillation

Bayer Xarelto reduced the risk of heart failure compared to vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation (NVAF) with chronic kidney disease (CKD). Bayer Korea shared the presentation of the XARENO study, a prospective observational study on nonvalvular atrial fibrillation patients with chronic kidney disease, at the 71st annual meeting of the … Read more